2001 is off to a running start for dealmakers in New England’s tech and life sciences sectors, it seems.
—Cambridge, MA-based Genocea Biosciences pulled in a tidy $35 million in a... Read more »
New England’s life sciences companies headed into the holiday break with mostly good news.
—Syndax Pharmaceuticals reported results from a mid-stage clinical trial which suggest that its lead drug, entinostat,... Read more »
Lots of nice deals to report this week from New England’s tech and life sciences sectors.
—E-mail archiving provider Sonian indicated to the SEC that it had raised $4 million in... Read more »
New England’s tech and life sciences companies were busy this week. Here are some of the deals they inked.
—Waltham, MA-based research tools and services provider Thermo Fisher Scientific (NYSE:TMO... Read more »
A number of New England tech and life sciences companies had deals to be thankful for this week.
—CloudBees, a startup soon to be headquartered in Boston, raised $4 million in... Read more »
This week saw deals inked in all corners of New England’s innovation ecosystem, but the biggie was in IT.
—Regulatory filings indicate that Kala Pharmaceuticals raised $3 million in an equity... Read more »
If you like deals with a “billion” in them, this was the week for you.
—Software maker Neohapsis of Cambridge, MA, raised $4.5 million in a deal led by New Venture... Read more »
Swiss pharma behemoth Novartis, already Cambridge, MA’s biggest corporate employer, planns to invest $600 million more in a new 4 acre office and lab complex here, according to a report on... Read more »
Dealmaking activity was on the light side this week in the New England tech and life sciences sectors, but there are still some interesting items to report.
—Search-engine developer Goby raised... Read more »
There’s all sorts of wisdom about how to find folks to invest in your startup, ranging from the obvious to the slightly stalkerish. Approach investors who’ve supported companies like yours in... Read more »
IT companies dominated this week’s deals news in New England. Here are some highlights.
—Online videogame maker Quick Hit raised $2.5 million in equity financing, according to an SEC filing.... Read more »
A French drugmaker’s bid to acquire one of New England’s biggest biotechs turned hostile this week. Read on for this, and some of the week’s less predictable deals news from the... Read more »
The birth and death of partnerships was the subject of much of this week’s news in New England’s life sciences sector.
—Rhythmia Medical raised $5 million in an equity offering... Read more »
It was New England’s public life sciences companies that made the most news in the sector this week.
—Ryan chatted with Mark Corrigan, CEO of Zalicus (NASDAQ: ZLCS), about the... Read more »
Big Blue is gobbling up all of New England’s IT companies—or at least that’s the impression you’d get from this week’s deals news.
—IBM (NYSE: IBM) announced it will acquire... Read more »
All eyes continued to be on Genzyme this week, but other New England life sciences companies had interesting developments to report as well.
—Good Start Genetics, a three-year-old Boston startup built... Read more »
New England’s life sciences companies inked the majority of this week’s deals, but several software firms had interesting business to report as well.
—Boston-based startup Rhythm Pharmaceuticals completed its Series A... Read more »
—Needham, MA-based Celldex Therapeutics announced that Pfizer (NYSE: PFE) had terminated a agreement in which it licensed Celldex’s experimental cancer vaccine rindopepimut, because it no longer views the drug as... Read more »
PrimeraDx, a Mansfield, MA-based developer of molecular diagnostic technology, has named Matthew F. McManus as its new president and chief executive, the company announced today. The startup, which raised $20 million... Read more »
[Updated 8/13/2010 9:30 EST. See below.] New England’s biotech and healthcare sector yielded a number of interesting stories this week.
—Joanna Horobin, CEO of Syndax Pharmaceuticals, confirmed that the... Read more »